Essential Thrombocythemia · line 2 · Anagrelide — ET 2L cytoreduction (HU-intolerant / HU-resistant)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-ANAGRELIDE-ET |
| ID | IND-ET-2L-ANAGRELIDE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-ET |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 SRC-PT1-HARRISON-2005 |
Notes
STUB — pending Clinical Co-Lead signoff. Standard-track 2L cytoreduction for HU-resistant/intolerant ET. NOTE: ET 2L algorithm (algo_et_2l.yaml) is MISSING from KB — flagged in audit report; should be authored from the algorithm-batch process, not unilaterally. Indication can still be activated by 1L algorithm fall-through with HU-resistance RF matching. UA access barrier dominant (not reimbursed for ET).
Used By
Algorithms
ALGO-ET-2L- ALGO-ET-2L